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Tiivistelmä - Referat – Abstract 
DBH-geeni koodaa dopamiinia hajottavaa entsyymiä, joka on liitetty palkkiojärjestelmään 
vaikuttamisen kautta erilaisiin riippuvuuksiin. DBH:n variaatioiden on todistettu liittyvän 
tupakointikäytänteisiin ja –tapoihin monessa tutkimuksessa. Viimeisimpänä rs3025343 liitettiin 
tupakoinnin lopettamiseen suuressa GWAS meta-analyysissa. Tutkimuksemme tavoitteena olikin 
replikoida kyseinen löydös suuressa väestötutkimusnäytteessämme. Lisäksi halusimme tutkia, 
vaikuttaisiko rs3025343 jonkin muun ympäristötekijän kautta vai itsenäisesti tupakoinnin 
lopettamiseen. 
 
Tutkimusnäytteemme on peräisin suomalaisesta väestönäytteestä, FINRISK-tutkimuksesta. Siihen 
lukeutuu 26,582 genotyypattua henkilöä tupakointistatuksineen. Analyysit rajasimme 11,926 
yksilöön, jotka olivat joko nykyisiä tupakoitsijoita (n=6,578) tai vähintään 6kk sitten tupakoinnin 
lopettaneita (n=5,348). Henkilöistä oli saatavilla myös kattavasti muita tietoja mukaan lukien 
sosioekonominen status, terveyteen liittyviä tapoja ja terveydentila, joita käytimme analyyseissä 
hyväksi.  
 
Yhteys rs3025343 ja tupakoinnin lopettamisen välillä (OR=1.12, p=0.094, 95%CI=0.98-1.30) 
osoittautui tutkimuksessamme identtiseksi GWAS-tutkimuksen kanssa (OR=1.12, 95%CI=1.08-1.18). 
Mikään testatuista fenotyypeistämme ei vaikuttanut tuohon yhteyteen merkitsevästi. Siviilisääty, 
koulutustaso, masennus, alkoholin käyttö, itseraportoitu terveys sekä COPD assosioituivat 
fenotyyppitekijöistä tupakoinnin lopettamiseen, mutta mikään edellämainituista assosiaatioista ei 
riippunut tutkimastamme genotyypistä.   
 
Vaikka tutkimustuloksemme ei ole tilastollisesti merkitsevä, efektikoko viittaa vahvasti siihen, että 
tutkimallamme polymorfismilla on jonkinasteinen yhteys tupakoinnin lopettamiseen. Merkitevyyden 
esiinsaamiseksi riittävällä voimalla (80%) otoskoon tulisi olla niinkin suuri kuin 36,092 tapausta ja 
29,343 kontrollia, koska harvinaisemman alleelin kantajia on suhteellisen vähän (7,1%). DBH-geenin 
variaatiot ovat osoittautuneet monessa tutkimuksessa olevan yhteydessä nikotiiniriippuvuuteen tai 
tupakoinnin lopettamiseen. Jos näitä yhteyksiä saadaan tutkittua lisää, on mahdollista että tietoja 
voitaisiin käyttää hyväksi tulevaisuudessa esim. yksilöllisesti räätälöidyssä tupakoinnin lopettamisen 
hoidossa.  
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Abstract 
Introduction 
Genetic variations in DBH-gene and its surroundings have been shown to associate with smoking behavior 
including smoking cessation in several studies. In this study we replicate and measure the effect size for 
association between DBH polymorphism rs3025343 and smoking cessation in a large population-based 
sample while examining environmental factors that could relate to the association.  
Methods 
We studied 11,926 adult subjects from four surveys of the National FINRISK Study. The analysis was 
restricted to either current or former smokers. Logistic and linear regression analyses were conducted to 
investigate the relationships of the SNP, covariates, smoking cessation and smoking severity (cotinine, 
CPD). Gene-environment interactions were tested by likelihood-ratio test. 
Results 
The association between rs3025343 and smoking cessation (prevalence odds ratio, OR=1.12, p=0.094, 
95%CI=0.98-1.30) was replicated identically with the GWAS study of The Tobacco and Genetics Consortium 
(OR=1.12, 95%CI=1.08-1.18). None of our tested phenotypes significantly influenced the association 
between rs3025343 and smoking cessation. Overall, marital status, education, depression, alcohol use, self-
rated health and COPD showed phenotypic associations with smoking cessation, but the association of 
various phenotypes with smoking cessation did not vary by genotype. 
Conclusions 
The current study replicates the effect size for the association between rs3025343 and smoking cessation 
despite lack of overall significance due to smaller sample size. We could not show environmental influences 
on the association of rs3025343 with smoking cessation.  
Implications 
Our study replicates the direction and strength of the association of DBH polymorphism rs3025343 with 
smoking cessation. We could not detect environmental influences on the strength of the association of 
rs3025343 with smoking cessation, but the limited power of our analysis needs to be taken into account. 
  
Introduction 
Quitting smoking is followed by immediate health benefits and a reduced risk of morbidity and mortality. 
Of the smokers that quit on their own only as few as 4-7% do not lapse back to smoking within the first year 
[1]. Even when utilizing cessation treatments, only 15-25% maintain abstinence for at least one year [2]. A 
better understanding of the genetic background of smoking cessation may provide the means to develop 
new and more efficient treatments, especially when the environmental factors are also taken into 
consideration. Heritable influences have been found for the ability to quit smoking [3-6]. However, the 
evidence linking the best known single genetic variants to smoking cessation has been conflicting in 
observation studies and clinical trials [7-9]. 
Nicotine enhances dopamine release by activating dopaminergic neurons in the mesolimbic reward 
pathway, which is involved in feeling pleasure when smoking. The DBH-gene encodes dopamine β-
hydroxylase, which catalyzes the conversion of dopamine to norepinephrine, and is also associated with 
smoking and drug dependencies.  
The SNP rs3025343, located 23kb upstream of DBH, is associated with smoking cessation according to a 
very large GWAS meta-analysis. The study, which included 64,924 ever smokers (OR=1.12, 95%CI=1.08-
1.18) found the G allele of rs3025343 to be more common among former than current smokers [10]. 
Another study with 3,441 chronic obstructive pulmonary disease (COPD) patients of European ancestry 
replicated this association by demonstrating similar results (OR=1.24, p=0.015) [11]. Both studies were 
observational. 
In a pooled analysis of two clinical trials reported by Leventhal and colleagues a haplotype of 6 DBH SNPs 
was found to predict abstinence at the end of cessation treatment and 6-month follow-up in study samples 
with high nicotine dependence [12]. Another study reported one DBH polymorphism to be associated with 
smoking severity among male schizophrenic smokers [13]. Although distinct from SNPs found significant in 
GWA studies, these findings support the hypothesis that DBH is an important candidate gene involved in 
smoking behavior.  
Our aim was to replicate the result of GWAS regarding rs3025343 and its association with smoking 
cessation in a large population-based sample. Furthermore, analyses of the relationship between 
rs3025343 and environmental factors associated with smoking cessation were conducted in order to 
observe the influence of such environmental factors on the strength of the association of rs3025343 with 
smoking cessation. Analyses of per-allele associations were conducted using a random effects method. 
 
Materials and methods 
Study sample 
Our sample was drawn from a Finnish population-based survey, the National FINRISK Study, which was first 
initiated in 1972 and has since then been carried out every five years using independent samples from four 
to six different parts of Finland depending on the year of survey [14]. We used data from cohorts 1992, 
1997, 2002 and 2007, comprising of 26,582 genotyped persons with known smoking status. Our analysis 
focused on the 11,926 genotyped subjects (41% women) who were either current smokers (n=6,578) or 
had quit smoking at least six months prior to the survey (n=5,348). Other self-reported information about 
their health-related habits, socioeconomic status and health status were obtained (see supplementary 
material for details on traits and genotyping). The mean age was 47.7 years (SD 12.7, range 25-74). 
Statistical analyses 
For testing the associations between covariates and quitting smoking within different genotypes we 
combined AA and AG genotypes to get two genotype classes; AX & GG. This was done due to AA genotype 
being too rare to permit separate analyses as is visualized in Table 1. We conducted logistic and linear 
regression analyses to investigate the relationships of the SNP, covariates, smoking cessation and smoking 
severity. To examine whether the associations of the gene with outcome differed significantly by categories 
of covariates, we fit models with and without an interaction of the SNP and covariate, and tested the 
significance of the change in model fit using a likelihood ratio test to derive the significance of the 
interaction. Age, gender, region and the year of questionnaire were adjusted in the analysis.  
All statistical analyses were performed using Stata 13.1 [15]. We report nominal p-values throughout the 
manuscript.  
 
Results 
The effect size (OR=1.12, p=0.094, 95%CI=0.98-1.3) for association between rs3025343 and smoking 
cessation in the FINRISK study sample was replicated identically with the earlier GWA study (OR=1.12, 
95%CI=1.08-1.18) although the association did not yield statistical significance [10]. This is shown in Table 1 
together with genotype information of the study sample. Rs3025343 G allele was more abundant in Eastern 
Finland (North-Karelia & Northern Savo) than elsewhere. Allele frequencies were similar regardless of the 
survey year.  
Table 2 shows the results of the association analysis between smoking cessation and rs3025343 in different 
phenotypes. While variation in OR-values was observed within phenotype classes, the likelihood-ratio tests 
show that none of the gene-environment interactions exceeded statistical significance (p<0.05). Thus, it 
appears that in this study, none of our tested phenotypes affects overall the strength of the association 
between rs3025343 and smoking cessation. Within variables, some individual categories showed nominally 
significant associations: among married persons (OR=1.18, 95%CI 1.00 to 1.39), among those drinking 14 or 
more drinks weekly (OR=1.60, 95%CI 1.01 to 2.52) and among those living the most eastern province of 
Finland (OR=1.52, 95%CI 1.05 to 2.21).  After adjustment for multiple testing, none of these is significant. 
The logistic regression analysis of the rs3025343 genotypes on smoking cessation in different phenotypes 
examined the strength of the association between phenotype and smoking cessation within the main 
genotype classes (first two columns of results) and overall (last column) (Supplementary table 1). The 
associations of phenotypes with smoking cessation were very similar in both genotype groups.  
However, Supplementary table 1 shows certain interesting results independent of genotype. Overall, 
having a diagnosis of bronchial asthma (OR=1.19, 95%CI=0.99-1.43) seems to make quitting smoking a little 
more probable while having COPD (OR=0.55, 95%CI=0.46-0.65) influences vice versa. Not surprisingly, 
quitting smoking is more likely for married people than singles, divorced or widowed. The same applies for 
high educated over low-educated people. Also, the better the self-rated health is, the greater the likelihood 
of having quit smoking. 
Quitting was more likely for people who have never used medication for depression than for those who 
have (Supplementary table 1). Expectedly, alcohol consumption was also strongly related to smoking 
cessation; greater the alcohol use, the smaller the likelihood of having quit smoking. The effect is best seen 
in heavy drinkers (OR=0.48) while abstainers comprise the reference group. 
The rs3025343 allele did not affect cotinine levels (p=0.78) nor CPD significantly (p=0.21) among current 
smokers, i.e we find no influence of the variant on amount of smoking. 
 
Discussion 
Several studies have reported association between common variants and smoking cessation although most 
studies have shown only modest associations. Nevertheless, a large meta-analysis has shown significant 
association between one single nucleotide polymorphism, rs3025343 near DBH gene, and smoking 
cessation [10] and a second large meta-analysis, in African Americans (David, 2012, PMC3365260), showed 
nominal significance between rs3025343 and smoking cessation. This finding has been replicated among 
COPD-patients [11]. Moreover, a candidate gene study reported rs3025343 to be nominally associated with 
continuous FTND score in European Americans (p=0.023) [16]. Based on present knowledge, FTND is one of 
the strongest predictors of smoking cessation. This indicates that rs3025343 may have an influence on the 
level of nicotine dependence and further, on smoking cessation [16]. Our study aimed to replicate the 
effect size for association between rs3025343 and smoking cessation that was reported in the meta-
analysis of the Tobacco and Genetics Consortium. We also evaluated the roles and associations of different 
environmental factors in order to exclude their possible influence on the relationship between the SNP and 
smoking cessation. The effect size for the association between rs3025343 and smoking cessation was 
identical to that observed in the meta-analysis (OR=1.12, p=0.094, 95%CI=0.98-1.3) although the 
association was not statistically significant in our study.  
In addition to studies investigating association between rs3025343 and smoking cessation, diverse studies 
have been carried out about other polymorphisms near or within DBH-gene and their relation to smoking 
cessation, usually through nicotine dependence level [17-21]. Although their results appear somewhat 
inconsistent, these studies demonstrate the potential role of DBH in smoking-related behaviors. The key 
limitation of many studies concerning DBH and smoking cessation and main reason for insignificant results 
is small sample size since even modest genetic influences usually require large study samples to be 
detected. Many polymorphisms of DBH associated with smoking cessation may be in strong linkage 
disequilibrium with each other.  
Rs3025343 does not cause a change in the amino acid residue in DBH since it is located in an intergenic 
region. Nevertheless, it could modify gene expression by affecting transcription either directly, through or 
together with other genetic variants in strong LD. The fact that only one DBH upstream variant (rs1611115) 
causes 51% of the variation in plasma-DBH activity in European-Americans strongly supports the 
conception that intergenic variants have a notable role in the regulation of gene expression [22].  
Despite our relatively large total study sample size, minor allele carriers are rather few (7.1%). Thus, 
especially when inspecting disease phenotypes, the number of minor allele carriers becomes very small 
when examining different phenotypes within genotypes. This leads to the statistical power being too low 
(22% according to the power analysis) for demonstrating reliable conclusions regarding minor or major 
allele’s specific influences on smoking cessation. This is the main limitation of our study. To increase power 
to 80%, as many as 36,092 cases and 29,343 controls would be required in total due to the low minor allele 
frequency. It should also be taken into account that we inspected and ruled out only a few carefully pre-
selected covariates.  
It is of interest that the DBH SNP has a different allelic distribution within Finland. The most probable 
explanation for the deviating allelic distribution is that the gene pool of people in Eastern and Western 
Finland are subject to influence from different regions together with the relatively small and regionally 
immobile population. Also, the role of that G allele on smoking cessation appeared to be more significant in 
North-Karelia (OR=1.52, 95%CI= 1.05-2.21) than elsewhere, which can partly be due to the different allelic 
distribution. The regional distribution however did not affect our other results, as we adjusted for region in 
all analyses. 
The current study replicates the effect size for the association between rs3025343 and smoking cessation 
although the association was not statistically significant. In addition we document associations of several 
covariates with smoking cessation.  
Funding 
VS was supported by the Finnish Foundations for Cardiovascular Research. Jaakko Kaprio has been 
supported by the Academy of Finland (grants 265240, 263278) and by the Sigrid Juselius Foundation. 
 
Declaration of Interests 
Tellervo Korhonen has consulted for Pfizer Finland on nicotine dependence in 2011-2016. Jaakko Kaprio has 
consulted for Pfizer Finland on nicotine dependence in 2012-2015. 
 
Acknowledgments  
References 
 [1] American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga. 2014. 
[2] Fiore MC, Jaen CR, Baker TB. Clinical Practice Guideline. 2008. Treating Tobacco Use and Dependence: 
2008 Update.  
[3] Xian H, Scherrer JF, Madden PA et al. The heritability of failed smoking cessation and nicotine 
withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res. 2003;5(2):245–254  
[4] Ray R, Mitra N, Baldwin D et al. Convergent evidence that choline acetyltransferase gene variation is 
associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacol. 
2010;35:1374–1382 
[5] Bergen AW, Conti DV, Van Den Berg D et al. Dopamine genes and nicotine dependence in treatment-
seeking and community smokers. Neuropsychopharmacol. 2009;34:2252–2264. 
[6] Bergen AW, Michel M, Nishita D et al. Drug Metabolizing Enzyme and Transporter Gene Variation, 
Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. Plos One, 2015;7(10) 
[7] Chen LS, Baker TB, Jorenby D et al. Genetic variation (CHRNA5), medication (combination nicotine 
replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depen. 2015;154:278-282. 
[8] Leung T, Bergen A, Munafò MR, Ruyck KD, Selby P, De Luca V. Effect of the rs1051730–rs16969968 
variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics. 2014;16(7):713-720.  
[9] Tyndale RF, Zhu AZX, George TP, et al. Lack of Associations of CHRNA5-A3-B4 Genetic Variants with 
Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. 
PLoS ONE 10.5, 2015, e0128109. doi:10.1371/journal.pone.0128109. 
[10] The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated 
with smoking behavior. Nat. Genet. 2010;42(5):441-447. doi:10.1038/ng.571.  
[11] Siedlinski M, Cho MH, Bakke P et al. Genome-wide association study of smoking behaviors in COPD 
patients. Thorax. 2011;66(10):894-902. 
[12] Leventhal AM, Lee W, Bergen AW et al. Nicotine dependence as a moderator of genetic influences on 
smoking cessation treatment outcome. Drug Alcohol Depen. 2014;138:109-117 
[13] Zhang XY, Chen DC, Xiu MH et al. Association of functional dopamine-beta-hydroxylase (DBH) 19 bp 
insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophr res. 
2012;141:48-53 
[14] Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-five-year trends in cardiovascular risk factors in 
Finland. Int J Epidemiol 2010;39:504-518.  
[15] StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009 
[16] Yang J, Wang S, Yang Z, Hodgkinson CA et al. The contribution of rare and common variants in 30 genes 
to risk nicotine dependence. Mol Psychiatry. 2014;1-12 
[17] McKinney EF, Walton RT, Yudkin P et al. Association between polymorphisms in dopamine metabolic 
enzymes ant tobacco consumption in smokers. Pharmacogenetics 2000 Aug;10(6):483-491. PubMed PMID: 
10975602. 
[18] Johnstone EC, Yudkin PL, Hey K et al. Genetic variation in dopaminergic pathways and short-term 
effectiveness of the nicotine patch. Pharmacogenetics 2004 Feb;14(2):83-90. PubMed PMID: 15077009.  
[19] Huang S, Cook DG, Hinks LJ et al. CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking 
behaviour and cotinine levels in 1518 UK adolescents. Pharmocogenet Genomics 2005 Dec;15(12):839-850. 
PubMed PMID: 16272956. 
[20] Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H. Prospective association of 
dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics 2010 
Apr;11(4):527-536 doi: 10.2217/pgs.10.1. PubMed PMID: 20350135. 
[21] Shiels MS, Huang HY, Hoffman SC et al. A Community-Based Study of Cigarette Smoking Behavior in 
Relation to Variation in Three Genes Involved in Dopamine Metabolism: Catechol-O-methyltransferase 
(COMT), Dopamine Beta-Hydroxylase (DBH) and Monoamine Oxidase-A (MAO-A). Prev Med 
2008;47(1):116-122. 
[22] Zabetian CP, Anderson GM, Buxbaum SG et al. A Quantitative-Trait Analysis of Human Plasma–
Dopamine Β-Hydroxylase Activity: Evidence for a Major Functional Polymorphism at the DBH Locus. Am J 
Hum Genet 2001;68:515-522 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary materials 
1. Phenotypes 
Smoking-related traits 
Smoking status was determined by three questions: “Have you ever smoked regularly, almost every day for 
at least a year?”, “Do you smoke now?” and “When was the last time you smoked?”. Based on this 
information, participants were divided into categories of daily smokers (smoked today or at least 
yesterday), occasional smokers (smoked two days to a month ago), recent quitters (quit one to six months 
ago) former smokers (quit one month ago or earlier) and never smokers (never smoked regularly).  
In the analyses of smoking cessation associations we used the groups of current smokers (comprising daily 
smokers above) and former smokers. Since relapse to smoking is highest within the 6 months of quitting 
smoking, recent quitters, i.e. smokers who had quit smoking less than 6 months prior to the survey (1.9% 
overall) were excluded from the analysis. Occasional smokers (1.6% overall) were also excluded from the 
analysis. Vartiainen et al. have shown that smoking status is reported accurately when assessed by cotinine 
analysis using these questions and definitions [1]. 
Participants were asked: “How many cigarettes (manufactured or self-rolled cigarettes, or equivalent 
amounts of cigars or pipe tobacco) do you smoke daily or smoked before quitting?” to measure cigarettes 
per day (CPD) amount. The answers were adapted as a quantitative measure of CPD that was analyzed as a 
quantitative trait when examining the association between CPD and our candidate SNP.  
 
Other traits 
We selected other traits for inclusion in the analysis based on their availability in the FINRISK database and 
their relevance for smoking cessation. These come from three domains of traits: alcohol use, smoking 
related disease and sociodemographic characteristics.  
Alcohol consumption was defined as two different traits for the analyses. First trait was categorical and the 
other dichotomous. Participants were asked: “How many glasses (restaurant measures) or bottles of 
alcohol beverages did you drink during last week?”. Based on this, alcohol consumption (g/week) was 
calculated by means of knowing ethanol content (grams) of each alcohol beverage. For categorical alcohol 
use analyses the quantitative alcohol consumption was first coded as standard drinks per week; one alcohol 
drink was defined as containing 12g of pure ethanol. After that, individuals were categorized as abstainers 
(less than 1 drink per week), light drinkers (3-7 drinks per week), moderate drinkers (7-14 drinks per week) 
and heavy drinkers (>14 drinks per week). For dichotomous alcohol use, we contrasted those drinking one 
or more drinks per week versus those either using no alcohol at all or drinking less than one drink per week. 
Information about certain smoking-related diseases; Angina pectoris, COPD and bronchial asthma, of 
participants was asked. They were asked if they have had these diseases (diagnosed by a physician) during 
last 12 months.  
Educational level was classified as low, middle and high by dividing self-reported years of formal education  
into study-year and cohort specific tertiles. Two most recent questionnaires also included the question 
“What is your highest educational level?” with seven different response options; (1) elementary school, (2) 
middle school, (3) trade school, (4) high school (5) vocational school (6) college and (7) academic degree. 
Marital status was asked by “What is your marital status” with alternatives of (1) Married, (2) Cohabitation, 
(3) Single, (4) Divorced and (5) Widowed. Married and cohabitation groups were combined as their 
influences on smoking cessation can be seen similar, while the latter three were combined as persons 
without regular partners. 
The subjects were asked about their self-rated health using the alternatives: (1) very good, (2) good, (3) 
average, (4) rather poor, and (5) very poor. 
Depression among participants was determined by question “When is the last time you have used 
medication for depression?” with alternatives: (1) During the past week, (2) 1–4 weeks ago, (3) 1–12 
months ago, (4) Over a year ago and (5) Never. This definition limits depression to the diagnosed form of it, 
which has the advantage that diagnosed cases are often more reliable than self-rated ones. On the other 
hand, many cases of depression are never diagnosed or have sought treatment. Thus the prevalence of 
depression in our analyses is lower than in reality.  
 
2. Analyses 
Age was used in the analyses as a continuous variable. In addition to that, gender was also adjusted.  
Region was one of the adjusted covariates in the analyses. FINRISK surveys are conducted in 6 different 
study areas: 1) North-Karelia province, 2) Northern Savo province, 3) cities of Turku and Loimaa, 4) cities of 
Helsinki and Vantaa, 5) Oulu province and 6) Lapland. Region was adjusted for in all analyses because of 
different allelic distribution of rs3025343 within Finland.  
The study year was also adjusted in analyses since the number of participants was dependent of the year 
and common knowledge and conceptions of smoking may have changed during twenty years. Allelic 
distribution was independent of the study year. 
 
3. Genotyping 
The SNP of our interest, rs3025343 was selected based on the meta-analysis of the Tobacco and Genetics 
Consortium [2] and supported by the study of Siedlinski and colleagues, which replicated the finding [3]. A 
second large meta-analysis, in African Americans (David, 2012, PMC3365260), showed nominal significance 
between rs3025343 and smoking cessation as well.  
DNA was derived from whole blood samples frozen immediately at the clinical study sites. DNA was 
extracted at the National Institute of Health and Welfare. Genotyping of the DNA samples was performed 
as described previously [4]. The success rate of rs3025343 was >0.99 and it was in Hardy Weinberg 
Equilibrium (p=0.87). Overall minor allele (A) frequency was 0.036.  
Plasma cotinine level was measured by gas chromatography from fasting plasma samples for participants 
who had reported to smoke currently [5]. We received both plasma cotinine level and genotype 
information of rs3025343 from 1495 current smokers in total from the 1992 survey.  
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Table 1. Genotype details of study sample and association between smoking cessation and rs3025343 per 
allele in Finnish population sample (logistic regression analysis), number of participants in different genotypes, 
p-value, odds ratio (OR) per allele and 95% confidence interval (95% CI) in columns.  
  AA AG GG total p OR 95% CI 
FINRISK         
Former 6 351 4,991 5,348    
Current 9 482 6,087 6,578    
All 15 833 11,078 11,926 0.094 1.12 0.98, 1.29 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Table 2. Association between smoking cessation and rs3025343 by strata of different phenotypes    
in the FINRISK population sample, prevalence odds ratios (ORs) and 95% confidence intervals (95% CIs) from 
logistic regression. Gene-environment interactions; p-value for interaction (pi) from likelihood-ratio test. 
Phenotype OR  95% CI pi n % 
Sex   0.50 11,926 100 
  Male 1.10 0.91, 1.33  7,030 59 
  Female 1.16 0.93, 1.45  4,896 41 
Marital status   0.62 11,909 100 
  Married 1.18 1.00, 1.39  8,749 73 
  Single 0.89 0.59, 1.36  1,533 13 
  Divorced 1.08 0.67, 1.75  1,334 11 
  Widowed 1.26 0.44, 3.63  293 2 
Education   0.19 11,806 99 
  Low 1.14 0.89, 1.47  4,260 36 
  Medium 1.28 0.99, 1.64  4,005 34 
  High 0.94 0.73, 1.22  3,541 30 
Region    11,926 100 
  North-Karelia 1.52 1.05, 2.21  2,321 19 
  Northern Savo 1.15 0.80, 1.66  2,313 19 
  Turku-Loimaa 1.14 0.85, 1.52  2,275 19 
  Helsinki-Vantaa 1.11 0.83, 1.49  2,558 21 
  Oulu 0.91 0,61, 1.35  1,648 14 
  Lapland 0.78 0.45, 1.37  811 7 
Angina pectoris   0.68 11,825 99 
  No 1.12 0.97, 1.30  11,295 95 
  Yes 1.08 0.52, 2.19   530 4 
Bronchial astma   0.40 11,814 99 
  No 1.14 0.99, 1.33  11,293 95 
  Yes 0.80 0.42, 1.55  521 4 
COPD   0.63 11,818 99 
  No 1.14 0.98, 1.32  11,157 94 
  Yes 0.82 0.40, 1.67  661 6 
Self-rated health   0.83 11,845 99 
  Very good 0.98 0.65, 1.47 	 1,330 11 
  Good 1.19 0.95, 1.49  4,932 41 
  Average 1.18 0.93, 1.50  4,402 37 
  Rather poor 0.97 0.58, 1.62  1,083 9 
  Very poor 0.70 0.15, 3.27  98 1 
Alcohol use during last week   11,926 100 
  Yes 1.14 0.96, 1.35  8,441 71 
  No 1.11 0.87, 1.44  3,485 29 
Alcohol use (drinks/week)  0.75 11,660 98 
  abstainers 1.11 0.86, 1.44  3,485 29 
  >0-3 1.10 0.78, 1.53  2,024 17 
  >3-7 1.10 0.78, 1.54  2,289 19 
  >7-14 1.15 0.81, 1.64  2,171 18 
  >14 1.60 1.01, 2.52  1,691 14 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
